Educational Webinar with Dr. Annette BOWYER, Lead Biomedical Scientist
The strategic acquisition reinforces Sebia’s global leadership in specialty diagnostics.
Educational Webinar with M. Jean Deenmamode, IFCC Working Group Chair
The HYDRASHIFT portfolio include IVD test to mitigate interferences seen in immunofixation result for patient treated with isatuximab or daratumumab.
Pitfalls and caveats in α1-antitrypsin deficiency testing: a guide for clinicians.
Evaluation of Sebia’s isoelectrofocusing kit for A1AT with HYDRASYS.